evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

458 questions · 466 findings · 48 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 87 · 18.7%GRADE not reported 82 · 17.6%Very low 153 · 32.8%Low 111 · 23.8%Moderate 19 · 4.1%High 14 · 3%

Perazine vs placebo

Leaving the study early · patients with schizophrenia

It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).

1 finding from 1 review

Perazine vs placebo

Global state change over time (no better or deterioration) · patients with schizophrenia

Perazine may leads to lower global state change over time (no better or deterioration) compared with placebo (low certainty).

1 finding from 1 review

Perazine vs placebo

Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with schizophrenia

Perazine showed no clear difference in overall mental state less than 30% BPRS reduction compared with placebo (low certainty).

1 finding from 1 review

Perazine vs placebo

Movement disorders number of participants receiving antiparkinson medication · patients with schizophrenia

It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with placebo (very low certainty).

1 finding from 1 review

Perazine vs placebo

Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
1 finding from 1 review
  • Perazine for schizophrenia 2014 · Cochrane Headline outcomes only
    no estimate extracted
    0 studies · 0 participants
    GRADE not reported

Perazine vs placebo

Satisfaction with care ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perazine vs placebo

Quality of life ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE vs placebo

Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses

It is very uncertain whether PIMOZIDE changes global state: relapse medium term (3‐12 months) Clinical diagnoses compared with PLACEBO (very low certainty).

1 finding from 1 review

PIMOZIDE vs placebo

Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE + ANY ANTIPSYCHOTIC vs placebo/no adjunctive treatment + antipsychotics

Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses

PIMOZIDE + ANY ANTIPSYCHOTIC showed no clear difference in global state: relapse medium term (3‐12 months) compared with ANTIPSYCHOTIC + PLACEBO; GRADE not reported.

1 finding from 1 review

PIMOZIDE vs placebo

Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE vs placebo

Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses

It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects: Parkinsonism… compared with PLACEBO (very low certainty).

1 finding from 1 review

PIMOZIDE vs placebo

Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses

It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).

1 finding from 1 review

PIMOZIDE vs placebo

Adverse effects: extrapyramidal adverse effects:Parkinsonism (tremor) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses

It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).

1 finding from 1 review